-+ 0.00%
-+ 0.00%
-+ 0.00%

Anavex Life Sciences Joins ACCESS-AD

Benzinga·01/13/2026 12:34:11
Listen to the news

Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease (AD) across real-world clinical settings. The five year program is funded by the European Commission's Innovative Health Initiative (IHI) and unites leading academic centers, technology developers, industry innovators and patient organizations to strengthen equitable access to timely and effective AD care.

ACCESS-AD launches at a pivotal time for Alzheimer's disease management in Europe. Recent approvals of antibody-based disease-modifying therapies (DMTs) have expanded the treatment landscape, but health systems continue to face substantial bottlenecks in diagnosis, patient stratification, imaging capacity and ongoing monitoring. With AD prevalence projected to exceed 19 million Europeans by 2050, scalable and accessible therapeutic options—especially those that reduce reliance on high-intensity healthcare infrastructure—are urgently needed.